Famed boot manufacturer Dr. Martens anticipates a significant financial impact from US tariffs this year. The company, known for its iconic footwear, has relocated most of its production to Vietnam due to increased import duties stemming from the trade dispute initiated by US President Donald Trump.
Dr. Martens expects a substantial hit in the “high single digit” million-pound range on its full-year profits due to these tariffs. In response, the company has shifted its manufacturing operations away from China, which previously represented half of its production, in order to mitigate the impact of US import tariffs.
Despite the tariff challenges, Dr. Martens remains optimistic about meeting its full-year profit forecasts ranging from £53 million to £60 million. The stock market announcement, however, caused a more than 10% drop in the company’s share price during early trading on Thursday.
The iconic bootmaker, renowned for its yellow-stitched boots, is committed to fully offsetting the additional tariff costs starting from the next fiscal year. Dr. Martens plans to achieve this goal through stringent cost management, flexible sourcing strategies, and targeted adjustments to its pricing in the USA.
In its latest financial update, Dr. Martens reported a reduction in losses to £11 million for the six months ending on September 28, compared to £12.3 million in the previous year. The company also saw a 0.8% increase in sales, reaching £327.3 million in the first half.
CEO Ije Nwokorie highlighted the brand’s strength, citing a 33% rise in shoe volumes and successful launches of new products like the Zebzag Laceless boot and the 1460 Rain boot. Despite market uncertainties and consumer caution, the company is optimistic about its plans for the upcoming year.
Investment director Russ Mould noted that Dr. Martens is taking steps towards profitability, although the recovery process may be gradual. The company’s efforts are reflected in its half-year results, showing improvements in full-price product sales, narrowed losses, and a stronger performance in the Americas region.
While there are positive indicators in the financial results, the market response was subdued, with early trading showing a decline in Dr. Martens’ share price, indicating investor dissatisfaction.
